This document is intended to provide guidance on the clinical evaluation of medicinal products in the treatment of rheumatoid arthritis (RA).
*The guideline has been formerly known as "Clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs (NSAIDs) for treatment of rheumatoid arthritis".
Keywords: Rheumatoid arthritis, disease modifying anti-rheumatic drugs, clinical development, CHMP, EMA, guideline